Emmett Cunningham, MD, PhD, MPH

Dr. Cunningham is a Managing Director at Clarus. He is on the Board of Directors of Annexon Biosciences, Graybug Vision, Restoration Robotics and SFJ Pharmaceuticals Group, is a Board observer for Lumos Pharma, and is on the Scientific Advisory Board of Aerie Pharmaceuticals. Prior to Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc, where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications.  He is Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001.   Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute.  Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit, a well-attended symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery and the American Society of Retinal Surgeons. The OIS brings together leading companies, clinicians, academics and investors in the ophthalmology space.


Thomas Dyrberg, MD, DMSc

Dr. Dyrberg is Managing Partner at Novo A/S. He is a member of the Boards of Directors of Delenex Therapeutics AG, Nuvelution Pharma, Inc., Ophthotech Corporation, PanOptica Inc., and Veloxis Pharmaceuticals A/S. Dr. Dyrberg held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, CA, USA. In 1990, he joined Novo Nordisk A/S, initially working in health care discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in health care clinical drug development. Dr. Dryberg attended the University of Copenhagen, where he obtained an MD degree and a DMSc degree.


Jason Fuller, PhD

Dr. Fuller joined NEA as a Principal in 2014 and focuses on investments in biopharmaceuticals.  Prior to joining NEA, Dr. Fuller was a Principal with Third Rock Ventures were he contributed to the creation and management of several companies, including NinePoint Medical, Kala Pharmaceuticals and most recently, Jounce Therapeutics where he served as Director of Corporate development after helping found the company.  Dr. Fuller earned his PhD at MIT under the supervision of Robert Langer as an NSF fellow, and received an MPhil from the University of Cambridge where he was a Churchill Scholar. He also holds a BS in Chemical Engineering from Michigan State University.


Campbell Murray, MD

Dr. Murray is a Managing Director for the Novartis Venture Funds in Cambridge, MA, USA. Prior to joining the fund, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects and as a physician in Auckland, New Zealand. Campbell is a New Zealand trained physician, Kauffman Fellow, and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio Therapeutics, Alios BioPharma, Annexon, BioNano Genomics, Galera Therapeutics, ImaginAb, and Neurovance.


Mike Powell, PhD, Chair

Dr. Powell joined Sofinnova in 1997 and SVP X is his seventh Sofinnova fund. He has 32 years of experience, including 15 years of R&D before entering the venture community. Dr. Powell has been involved in more than 50 clinical programs and is the author of 90 publications and books, including a 1,000-page treatise on vaccine design. Before joining Sofinnova, he was Group Leader of drug delivery at Genentech, as well as Director of Product Development at Cytel. Before this he was Senior Scientist and Project Team Leader at Syntex Research. Dr. Powell received his PhD in Physical Chemistry from the University of Toronto and carried out postdoctoral studies in Bio-organic Chemistry at the University of California as a National Science and Engineering Research Council Scholar.


Mel Sorensen, MD

Dr. Sorensen has been President and Chief Executive Officer of Galera Therapeutics since 2012. He is a Medical Oncologist who has spent 7-8 years each in patient care (oncology fellowship at the Mayo Clinic), in academia (Senior Investigator at the National Institutes of Health), and in leadership positions in clinical development in the pharmaceutical industry (Bayer and GlaxoSmithKline).  Since 2004, he has served as President & CEO of private venture-funded biotechs. Dr. Sorensen has raised over $300 million in multiple private financing rounds and has led licensing deals for several preclinical and clinical-stage compounds. He also serves as a Director or Chairman of other biotech companies, including Oncopia Therapeutics, Esanik Therapeutics and Context Therapeutics, and is an advisor to the Biomarkers Consortium of the National Institutes of Health and to the Irish Cancer Society.